Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia.

FLT3-ITD acute myeloid leukemia next-generation sequencing

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
09 Jun 2020
Historique:
received: 30 01 2020
accepted: 14 05 2020
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 25 6 2020
Statut: epublish

Résumé

A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage therapy for these patients. We studied all adult patients with relapsed/refractory (R/R) AML who were treated with HiDAC/MITO in our center between the years 2008-2017. To determine whether responding patients harbored a unique molecular signature, we performed targeted next-generation sequencing (NGS) on a subset of patients. The study cohort consisted of 172 patients with a median age of 54 years (range 18-77). The composite complete remission rate was 58%; 11 patients (6%) died during salvage therapy. Median survival was 11.4 months with a 1-year survival rate of 48%. In multivariate analysis favorable risk cytogenetics [Odds ratio (OR)=0.34, confidence interval (CI) 95%, 0.17-0.68;

Identifiants

pubmed: 32577167
doi: 10.18632/oncotarget.27618
pii: 27618
pmc: PMC7289527
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2233-2245

Informations de copyright

Copyright: © 2020 Canaani et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST None.

Références

Cancer Discov. 2019 Aug;9(8):1050-1063
pubmed: 31088841
Leukemia. 2017 Jun;31(6):1306-1313
pubmed: 28138160
Am J Hematol. 2013 Jul;88(7):601-5
pubmed: 23619977
Leukemia. 2017 May;31(5):1217-1220
pubmed: 28096533
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Blood. 2019 Feb 14;133(7):676-687
pubmed: 30510081
Br J Haematol. 2016 Sep;174(5):700-10
pubmed: 27118319
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Leukemia. 1993 Apr;7(4):549-52
pubmed: 8464233
Nature. 2018 Jul;559(7712):125-129
pubmed: 29950729
Blood. 2010 Dec 23;116(26):5818-23; quiz 6153
pubmed: 20923968
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Blood. 2000 Sep 15;96(6):2055-61
pubmed: 10979947
Nat Commun. 2019 Jan 16;10(1):244
pubmed: 30651561
Leuk Lymphoma. 1993 Mar;9(4-5):343-50
pubmed: 8394169
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
J Clin Oncol. 2013 Apr 1;31(10):1293-301
pubmed: 23439754
N Engl J Med. 2007 Jan 25;356(4):348-59
pubmed: 17251531
Leukemia. 2011 Jun;25(6):939-44
pubmed: 21331073
Leuk Res. 1999 Sep;23(9):787-94
pubmed: 10475617
Leukemia. 1994 Jan;8(1):6-10
pubmed: 8289499
Blood. 2009 Apr 16;113(16):3666-72
pubmed: 19020306
J Clin Oncol. 1985 Jul;3(7):992-7
pubmed: 3894588
Lancet Oncol. 2015 Sep;16(9):1025-1036
pubmed: 26234174
Haematologica. 2016 Jul;101(7):839-45
pubmed: 27036160
Blood. 2009 Nov 5;114(19):4027-33
pubmed: 19710500
Leukemia. 2015 Feb;29(2):312-20
pubmed: 25113226
Am J Hematol. 2018 Jun 15;:
pubmed: 29905379
J Clin Oncol. 2012 Jul 10;30(20):2492-9
pubmed: 22585697
Leukemia. 2007 Jan;21(1):66-71
pubmed: 17051246
Genes Chromosomes Cancer. 2019 Dec;58(12):875-888
pubmed: 31393631
Blood. 2015 May 21;125(21):3359-60
pubmed: 25999448
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
J Clin Oncol. 2014 Jun 20;32(18):1919-26
pubmed: 24841975
J Clin Oncol. 2005 Mar 20;23(9):1969-78
pubmed: 15632409
Ann Hematol. 2018 Jul;97(7):1115-1153
pubmed: 29680875
Leuk Res. 1999 Aug;23(8):695-700
pubmed: 10456666
Haematologica. 2010 Nov;95(11):1857-64
pubmed: 20634493
N Engl J Med. 2012 Mar 22;366(12):1079-89
pubmed: 22417203
Blood. 2015 Jul 16;126(3):319-27
pubmed: 25852056
Leukemia. 1993 Oct;7(10):1496-9
pubmed: 8412309
J Intern Med. 2019 Apr;285(4):407-418
pubmed: 30372796
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Haematologica. 2016 Nov;101(11):1351-1358
pubmed: 27540133
Clin Cancer Res. 2018 May 1;24(9):2060-2073
pubmed: 29437791
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Blood. 2016 Jan 7;127(1):53-61
pubmed: 26660429
Ann Hematol. 1999 Sep;78(9):418-25
pubmed: 10525830
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Br J Haematol. 2001 Jan;112(1):127-37
pubmed: 11167793
Leukemia. 1994 Nov;8(11):1847-53
pubmed: 7967730
Br J Haematol. 2011 Oct;155(2):182-9
pubmed: 21848522
Br J Haematol. 2011 Nov;155(4):413-9
pubmed: 21910721
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938

Auteurs

Jonathan Canaani (J)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Meital Nagar (M)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Gabriel Heering (G)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Chen Gefen (C)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Ronit Yerushalmi (R)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Noga Shem-Tov (N)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Yulia Volchek (Y)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Drorit Merkel (D)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Abraham Avigdor (A)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Avichai Shimoni (A)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Ninette Amariglio (N)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Gidi Rechavi (G)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Arnon Nagler (A)

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Classifications MeSH